Investing.com -- Castle Biosciences (NASDAQ:CSTL)股价下跌9%，此前地区Medicare承包商Novitas最终决定不承保该公司的一项癌症检测。Novitas Medicare行政承包商 (MAC)确认了一项地方承保决定 (LCD)，导致不承保Castle的DecisionDx-SCC检测。这一决定将于2月23日生效。

Congress recently pulled a similar stunt on Medicare beneficiaries. But in this case, the result was more than just ...

The U.S. government on Friday proposed 2026 reimbursement rates for Medicare Advantage plans run by private insurers that ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

The Biden administration’s final regulation affecting the Medicare Advantage industry would come with a much lighter touch ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

MA plans are substantially overpaid compared to traditional Medicare. Much of these overpayments benefit the MA plans rather ...

Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to ...

Politico has acquired an early list from Republican lawmakers that shows the programs they're considering slashing from the ...

The Medicare Advantage Open Enrollment Period (Jan 1–Mar 31) lets you switch plans or adjust coverage. Review your options to ...

加利福尼亚州尔湾 - 市值目前为3800万美元的分子诊断公司Oncocyte Corp. (NASDAQ: OCX)宣布,其VitaGraft Kidney肾移植患者检测获得了Medicare扩大覆盖范围。这一决定源于一项研究表明该检测在早期发现移植排斥反应方面的有效性。根据 InvestingPro 的数据,尽管公司面临重大运营挑战,但其股票目前的交易价格接近其公允价值。分子诊断计划 ...

Mansinh Chaudhari, 55, of Illinois, pleaded guilty before U.S. District Judge Michael E. Farbiarz in Newark federal court to ...